NASDAQ:LYEL Lyell Immunopharma - LYEL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Lyell Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.01 -0.02 (-0.99%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.95▼$2.0350-Day Range$1.97▼$3.4852-Week Range$1.83▼$8.74Volume964,807 shsAverage Volume1.21 million shsMarket Capitalization$501.72 millionP/E RatioN/ADividend YieldN/APrice Target$6.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Lyell Immunopharma MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside231.7% Upside$6.67 Price TargetShort InterestBearish15.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.31Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.15) to ($1.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.74 out of 5 starsMedical Sector841st out of 1,005 stocksPharmaceutical Preparations Industry406th out of 486 stocks 3.2 Analyst's Opinion Consensus RatingLyell Immunopharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.67, Lyell Immunopharma has a forecasted upside of 231.7% from its current price of $2.01.Amount of Analyst CoverageLyell Immunopharma has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.06% of the float of Lyell Immunopharma has been sold short.Short Interest Ratio / Days to CoverLyell Immunopharma has a short interest ratio ("days to cover") of 16.2, which indicates bearish sentiment.Change versus previous monthShort interest in Lyell Immunopharma has recently increased by 5.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLyell Immunopharma does not currently pay a dividend.Dividend GrowthLyell Immunopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LYEL. Previous Next 2.4 News and Social Media Coverage News SentimentLyell Immunopharma has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Lyell Immunopharma this week, compared to 1 article on an average week.MarketBeat Follows4 people have added Lyell Immunopharma to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lyell Immunopharma insiders have not sold or bought any company stock.Percentage Held by Insiders25.80% of the stock of Lyell Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.04% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lyell Immunopharma are expected to decrease in the coming year, from ($1.15) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyell Immunopharma is -2.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyell Immunopharma is -2.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyell Immunopharma has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lyell Immunopharma (NASDAQ:LYEL) StockLyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Read More Receive LYEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LYEL Stock News HeadlinesMarch 26, 2023 | finance.yahoo.comLyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 47% stakeMarch 25, 2023 | americanbankingnews.comLyell Immunopharma (NASDAQ:LYEL) Hits New 12-Month Low at $1.83March 26, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 22, 2023 | americanbankingnews.comLyell Immunopharma (NASDAQ:LYEL) Trading Down 3.5%March 18, 2023 | americanbankingnews.comLyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Large Growth in Short InterestMarch 1, 2023 | finanznachrichten.deLyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022March 1, 2023 | finance.yahoo.comLyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022March 1, 2023 | finance.yahoo.comLyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue EstimatesMarch 26, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. January 3, 2023 | finance.yahoo.comLyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare ConferenceDecember 23, 2022 | finance.yahoo.comLyell Immunopharma (NASDAQ:LYEL) investors are sitting on a loss of 63% if they invested a year agoDecember 16, 2022 | finance.yahoo.comLynn Seely steps into top role at cancer-fighting company Lyell ImmunopharmaDecember 15, 2022 | marketwatch.comLyell Immunopharma Taps Lynn Seely to Succeed Liz Homans as CEODecember 15, 2022 | markets.businessinsider.comLyell Immunopharma CEO Liz Homans Steps Down; Names Lynn Seely ReplacemetDecember 15, 2022 | finance.yahoo.comLyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive OfficerDecember 9, 2022 | finance.yahoo.comLyell Immunopharma (LYEL) Loses 21.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerDecember 1, 2022 | finance.yahoo.comLyell Immunopharma to Participate in BofA Securities Biotech ConferenceNovember 12, 2022 | finance.yahoo.comEarnings Beat: Lyell Immunopharma, Inc. (NASDAQ:LYEL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsNovember 12, 2022 | benzinga.comGoldman Sachs Downgrades Lyell Immunopharma to NeutralNovember 10, 2022 | finance.yahoo.comLyell Immunopharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 10, 2022 | finance.yahoo.comLyell Immunopharma to Participate in Barclays Virtual Fireside Chat SeriesNovember 8, 2022 | finance.yahoo.comLyell Immunopharma (LYEL) Reports Q3 Loss, Lags Revenue EstimatesNovember 8, 2022 | finance.yahoo.comLyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial ResultsNovember 7, 2022 | finance.yahoo.comLyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid TumorsNovember 4, 2022 | finance.yahoo.comLyell Immunopharma (LYEL) Expected to Beat Earnings Estimates: Should You Buy?November 2, 2022 | finance.yahoo.comLyell Immunopharma to Participate in Credit Suisse Healthcare ConferenceOctober 17, 2022 | finance.yahoo.comInstitutional owners may take dramatic actions as Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) recent 7.5% drop adds to one-year lossesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LYEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address LYEL Company Calendar Last Earnings2/28/2023Today3/26/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LYEL CUSIPN/A CIK1806952 Webwww.lyell.com Phone650-695-0677FaxN/AEmployees219Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.67 High Stock Price Forecast$9.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+231.7%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-183,120,000.00 Net Margins-216.24% Pretax Margin-216.24% Return on Equity-21.53% Return on Assets-18.27% Debt Debt-to-Equity RatioN/A Current Ratio17.59 Quick Ratio17.59 Sales & Book Value Annual Sales$84.68 million Price / Sales5.92 Cash FlowN/A Price / Cash FlowN/A Book Value$3.34 per share Price / Book0.60Miscellaneous Outstanding Shares249,610,000Free Float185,210,000Market Cap$501.72 million OptionableNot Optionable Beta-1.68 Key ExecutivesDr. Richard D. Klausner M.D. (Age 70)Founder & Exec. Chairman Comp: $510.17kMs. Elizabeth Homans (Age 56)CEO & Director Comp: $988.85kMr. Charles W. Newton (Age 51)Chief Financial Officer Comp: $1.75MMr. Stephen J. Hill (Age 52)Chief Operating Officer Comp: $808.12kProf. Stanley R. Riddell M.D.Founder & Scientific AdvisorDr. Crystal L. Mackall M.D.Founder & Scientific AdvisorNellie DilleryDirector of AccountingMr. Richard Goold Ph.D. (Age 62)Chief Information Officer Dr. Gary Lee Ph.D. (Age 45)Chief Scientific Officer Ellen RoseVP of Communications & Investor RelationsMore ExecutivesKey CompetitorsAerovate TherapeuticsNASDAQ:AVTEBioXcel TherapeuticsNASDAQ:BTAIAclaris TherapeuticsNASDAQ:ACRSEntrada TherapeuticsNASDAQ:TRDAMorphoSysNASDAQ:MORView All CompetitorsInsiders & InstitutionsMorgan StanleySold 196,201 shares on 2/15/2023Ownership: 0.088%E Fund Management Co. Ltd.Bought 15,986 shares on 2/15/2023Ownership: 0.012%Mariner LLCBought 10,185 shares on 2/15/2023Ownership: 0.004%Susquehanna International Group LLPSold 65,914 shares on 2/14/2023Ownership: 0.022%Alpine Global Management LLCBought 27,051 shares on 2/14/2023Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions LYEL Stock - Frequently Asked Questions Should I buy or sell Lyell Immunopharma stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LYEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LYEL, but not buy additional shares or sell existing shares. View LYEL analyst ratings or view top-rated stocks. What is Lyell Immunopharma's stock price forecast for 2023? 3 Wall Street analysts have issued 1 year price objectives for Lyell Immunopharma's stock. Their LYEL share price forecasts range from $4.00 to $9.00. On average, they anticipate the company's share price to reach $6.67 in the next twelve months. This suggests a possible upside of 231.7% from the stock's current price. View analysts price targets for LYEL or view top-rated stocks among Wall Street analysts. How have LYEL shares performed in 2023? Lyell Immunopharma's stock was trading at $3.47 at the beginning of 2023. Since then, LYEL stock has decreased by 42.1% and is now trading at $2.01. View the best growth stocks for 2023 here. When is Lyell Immunopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our LYEL earnings forecast. How were Lyell Immunopharma's earnings last quarter? Lyell Immunopharma, Inc. (NASDAQ:LYEL) issued its quarterly earnings results on Tuesday, February, 28th. The company reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.28. The firm had revenue of $48.39 million for the quarter, compared to analyst estimates of $2.85 million. Lyell Immunopharma had a negative trailing twelve-month return on equity of 21.53% and a negative net margin of 216.24%. What ETFs hold Lyell Immunopharma's stock? ETFs with the largest weight of Lyell Immunopharma (NASDAQ:LYEL) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB) and iShares Biotechnology ETF (IBB). When did Lyell Immunopharma IPO? (LYEL) raised $425 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 25,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO. What is Lyell Immunopharma's stock symbol? Lyell Immunopharma trades on the NASDAQ under the ticker symbol "LYEL." Who are Lyell Immunopharma's major shareholders? Lyell Immunopharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (1.47%), Geode Capital Management LLC (1.22%), Charles Schwab Investment Management Inc. (0.45%), Baillie Gifford & Co. (0.31%), Bank of America Corp DE (0.26%) and JPMorgan Chase & Co. (0.23%). Insiders that own company stock include Cathy Friedman and Richard Klausner. View institutional ownership trends. How do I buy shares of Lyell Immunopharma? Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lyell Immunopharma's stock price today? One share of LYEL stock can currently be purchased for approximately $2.01. How much money does Lyell Immunopharma make? Lyell Immunopharma (NASDAQ:LYEL) has a market capitalization of $501.72 million and generates $84.68 million in revenue each year. The company earns $-183,120,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. How many employees does Lyell Immunopharma have? The company employs 219 workers across the globe. How can I contact Lyell Immunopharma? The official website for the company is www.lyell.com. The company can be reached via phone at 650-695-0677 or via email at erose@lyell.com. This page (NASDAQ:LYEL) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.